Seattle's Juno Therapeutics, at work on treatments that train the immune system to better fight cancer, has signed a deal to expand its pipeline of therapies, licensing a complementary candidate developed by the National Cancer Institute.
iRhythm has received a CE mark in Europe for its continuous heart monitoring Zio Service. The technology enables up to 14 days of continuous heart monitoring via a wireless patch; it includes analytical software, as well as report to the physician. In addition, iRhythm has partnered with cardiology distributor CardioLogic to market Zio in the U.K. for the diagnosis of atrial fibrillation and other cardiac arrhythmias.
Catalent has signed on with Concord, MA-based Valerion Therapeutics to help develop delivery technology for the company's line of orphan genetic treatments.
Recipharm has purchased a manufacturing facility from Flamel Technologies in Pessac, France, for $13.2 million. The move is part of an effort to incorporate drug delivery technologies into its contract development business.
Microdermis' antiseptic skin product Provodine--which incorporates a novel dermal delivery system--has been adopted by the U.S. Army and will be used in West Africa against ebolavirus.
Sanofi has pulled back the curtain on its plans for R&D in the post-Chris Viehbacher future, outlining a deeply intertwined relationship with German outsourcer Evotec designed to help the company cut costs as it shares the risks and rewards of building out its pipeline.
Edison Nation Medical and Mount Sinai Health System have struck a partnership focused on bringing medical device and other healthcare-related inventions to market.
German diagnostic imaging outfit nanoPET Pharma is teaming up with Boehringer Ingelheim to develop diagnostic agents for preclinical drug development, building on a previous relationship between the two companies and opening the door for future collaboration.
Johnson & Johnson's plan to grow its pipeline with deal-scouting outposts around the globe is beginning to pay off, as the drugmaker's London lookout has brought in what could be a promising approach to rheumatoid arthritis.
Royal Philips will make healthcare informatics a key emphasis as it pushes toward its previously announced shift toward organizing the company to focus on what it has dubbed "HealthTech."